BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $174,678 | $208,742 | $208,742 | $208,742 |
| - Cash | $1,698 | $0 | $0 | $0 |
| + Debt | $0 | $70 | $43 | $37 |
| Enterprise Value | $172,980 | $208,812 | $208,785 | $208,779 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$80,655 | -$64,679 | -$4 | -$43 |
| % Margin | – | – | – | – |
| Net Income | -$74,275 | -$64,699 | -$4 | -$43 |
| % Margin | – | – | – | – |
| EPS Diluted | 0.46 | -0.002 | 0 | -0.002 |
| % Growth | 23,100% | – | 100% | – |
| Operating Cash Flow | -$764 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$764 | $0 | $0 | $0 |